Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Clinical implications of coronary pressure measurement after stent implantation.

Matsuo A, Fujita H, Tanigaki T, Shimonaga T, Ueoka A, Tsubakimoto Y, Sakatani T, Kimura S, Inoue K, Kitamura M.

Cardiovasc Interv Ther. 2013 Apr;28(2):170-7. doi: 10.1007/s12928-012-0147-7. Epub 2012 Nov 18.

PMID:
23161151
2.

Long-Term Clinical Outcomes of Fractional Flow Reserve-Guided Versus Routine Drug-Eluting Stent Implantation in Patients With Intermediate Coronary Stenosis: Five-Year Clinical Outcomes of DEFER-DES Trial.

Park SH, Jeon KH, Lee JM, Nam CW, Doh JH, Lee BK, Rha SW, Yoo KD, Jung KT, Cho YS, Lee HY, Youn TJ, Chung WY, Koo BK.

Circ Cardiovasc Interv. 2015 Dec;8(12):e002442. doi: 10.1161/CIRCINTERVENTIONS.115.002442.

3.

Utility of myocardial fractional flow reserve for prediction of restenosis following sirolimus-eluting stent implantation.

Ishii H, Kataoka T, Kobayashi Y, Tsumori T, Takeshita H, Matsumoto R, Shirai N, Nishioka H, Hasegawa T, Nakata S, Shimada Y, Ehara S, Muro T, Yoshiyama M.

Heart Vessels. 2011 Nov;26(6):572-81. doi: 10.1007/s00380-010-0105-1. Epub 2011 Jan 8.

PMID:
21221600
4.

Relation of fractional flow reserve after drug-eluting stent implantation to one-year outcomes.

Nam CW, Hur SH, Cho YK, Park HS, Yoon HJ, Kim H, Chung IS, Kim YN, Kim KB, Doh JH, Koo BK, Tahk SJ, Fearon WF.

Am J Cardiol. 2011 Jun 15;107(12):1763-7. doi: 10.1016/j.amjcard.2011.02.329. Epub 2011 Apr 8.

PMID:
21481828
5.
6.

Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience.

Rigatelli G, Cardaioli P, Dell'Avvocata F, Giordan M, Vassilev D, Fraccaro C, Roncon L, Faggian G.

Cardiovasc Revasc Med. 2014 Mar;15(2):76-9. doi: 10.1016/j.carrev.2014.01.008. Epub 2014 Jan 20.

PMID:
24560299
7.

Clinical Relevance of Poststent Fractional Flow Reserve After Drug-Eluting Stent Implantation.

Doh JH, Nam CW, Koo BK, Lee SY, Choi H, Namgung J, Kwon SU, Kwak JJ, Kim HY, Choi WH, Lee WR.

J Invasive Cardiol. 2015 Aug;27(8):346-51.

8.

Fractional flow reserve for the prediction of cardiac events after coronary stent implantation: results of a multivariate analysis.

Klauss V, Erdin P, Rieber J, Leibig M, Stempfle HU, König A, Baylacher M, Theisen K, Haufe MC, Sroczynski G, Schiele T, Siebert U.

Heart. 2005 Feb;91(2):203-6.

9.

Physiological evaluation of the provisional side-branch intervention strategy for bifurcation lesions using fractional flow reserve.

Koo BK, Park KW, Kang HJ, Cho YS, Chung WY, Youn TJ, Chae IH, Choi DJ, Tahk SJ, Oh BH, Park YB, Kim HS.

Eur Heart J. 2008 Mar;29(6):726-32. doi: 10.1093/eurheartj/ehn045. Epub 2008 Feb 28.

PMID:
18308689
10.

Clinical and physiological outcomes of fractional flow reserve-guided percutaneous coronary intervention in patients with serial stenoses within one coronary artery.

Kim HL, Koo BK, Nam CW, Doh JH, Kim JH, Yang HM, Park KW, Lee HY, Kang HJ, Cho YS, Youn TJ, Kim SH, Chae IH, Choi DJ, Kim HS, Oh BH, Park YB.

JACC Cardiovasc Interv. 2012 Oct;5(10):1013-8. doi: 10.1016/j.jcin.2012.06.017.

11.

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis.

Nojima Y, Yasuoka Y, Kume K, Adachi H, Hattori S, Matsutera R, Kohama Y, Sasaki T.

Coron Artery Dis. 2014 Dec;25(8):638-44. doi: 10.1097/MCA.0000000000000159.

12.

Functional assessment of jailed side branches in coronary bifurcation lesions using fractional flow reserve.

Ahn JM, Lee JY, Kang SJ, Kim YH, Song HG, Oh JH, Park JS, Kim WJ, Lee SW, Lee CW, Kim JJ, Park SW, Park SJ.

JACC Cardiovasc Interv. 2012 Feb;5(2):155-61. doi: 10.1016/j.jcin.2011.10.015.

13.

Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study.

Pijls NH, Fearon WF, Tonino PA, Siebert U, Ikeno F, Bornschein B, van't Veer M, Klauss V, Manoharan G, Engstrøm T, Oldroyd KG, Ver Lee PN, MacCarthy PA, De Bruyne B; FAME Study Investigators..

J Am Coll Cardiol. 2010 Jul 13;56(3):177-84. doi: 10.1016/j.jacc.2010.04.012. Epub 2010 May 28.

14.

Comparison of drug-eluting stent with bare metal stent for distal de novo unprotected left main coronary artery stenosis. A propensity score-matched cohort study.

Hsueh SK, Wu CJ, Fang HY, Hsieh YK, Fang CY, Chen CJ, Chen SM, Yang CH, Yip HK, Chen MC, Fu M, Cheng CI.

Circ J. 2011;75(2):290-8. Epub 2010 Dec 10.

15.

Clinical and procedural predictors of suboptimal outcome after the treatment of drug-eluting stent restenosis in the unprotected distal left main stem: the Milan and New-Tokyo (MITO) registry.

Takagi K, Ielasi A, Shannon J, Latib A, Godino C, Davidavicius G, Mussardo M, Ferrarello S, Figini F, Carlino M, Montorfano M, Chieffo A, Nakamura S, Colombo A.

Circ Cardiovasc Interv. 2012 Aug 1;5(4):491-8. doi: 10.1161/CIRCINTERVENTIONS.111.964874. Epub 2012 Jul 31.

16.

Fractional flow reserve predicts major adverse cardiac events after coronary stent implantation.

Rieber J, Schiele TM, Erdin P, Stempfle HU, König A, Erhard I, Segmiller T, Baylacher M, Theisen K, Haufe MC, Siebert U, Klauss V.

Z Kardiol. 2002;91 Suppl 3:132-6.

PMID:
12641028
17.

Clinical significance of fractional flow reserve for evaluation of functional lesion severity in stent restenosis and native coronary arteries.

Krüger S, Koch KC, Kaumanns I, Merx MW, Hanrath P, Hoffmann R.

Chest. 2005 Sep;128(3):1645-9.

PMID:
16162770
18.

A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.

Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Kang SJ, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ.

JACC Cardiovasc Interv. 2011 Mar;4(3):310-6. doi: 10.1016/j.jcin.2010.12.006.

19.

Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: retrospective analysis of 4 Japanese hospitals.

Kitahara H, Kobayashi Y, Takebayashi H, Fujimoto Y, Nakamura Y, Kuroda N, Himi T, Miyazaki A, Haruta S, Komuro I.

Circ J. 2009 May;73(5):867-71. Epub 2009 Apr 9.

20.

Diagnostic implication of change in b-type natriuretic peptide (BNP) for prediction of subsequent target lesion revascularization following silorimus-eluting stent deployment.

Hasumi E, Iwata H, Kohro T, Manabe I, Kinugawa K, Morisaki N, Ando J, Sawaki D, Takahashi M, Fujita H, Yamashita H, Ako J, Hirata Y, Komuro I, Nagai R.

Int J Cardiol. 2013 Sep 30;168(2):1429-34. doi: 10.1016/j.ijcard.2012.12.046. Epub 2013 Jan 7.

PMID:
23302112

Supplemental Content

Support Center